Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2023; 15(6): 786-796
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.786
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.786
Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
Yu-Qi Li, Ya-Nuo Li, Department of Pathophysiology, School of Basic Medicine, Binzhou Medical University, Yantai 264000, Shandong Province, China
Lei Xin, Department of Gastrointestinal Surgery, Yantaishan Hospital, Yantai 264000, Shandong Province, China
Yu-Chi Zhao, Department of Surgery, Yantaishan Hospital, Yantai 264000, Shandong Province, China
Shang-Qi Li, The First School of Clinical Medicine, Binzhou Medical University, Yantai 264000, Shandong, China, Yantai 264000, Shandong Province, China
Author contributions: Li YQ prepared and drafted the manuscript; Xin L made the critical revision; Zhao YC edited the manuscript; Li SQ collected the literature review; Li YN approved the final version.
Conflict-of-interest statement: All the authors have declared no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Nuo Li, PhD, Professor, Department of Pathophysiology, School of Basic Medicine, Binzhou Medical University, No. 346 Guanhai Road, Laishan District, Yantai 264000, Shandong Province, China. liyanuo@bzmc.edu.cn
Received: March 6, 2023
Peer-review started: March 6, 2023
First decision: April 12, 2023
Revised: April 27, 2023
Accepted: May 9, 2023
Article in press: May 9, 2023
Published online: June 27, 2023
Processing time: 111 Days and 6.1 Hours
Peer-review started: March 6, 2023
First decision: April 12, 2023
Revised: April 27, 2023
Accepted: May 9, 2023
Article in press: May 9, 2023
Published online: June 27, 2023
Processing time: 111 Days and 6.1 Hours
Core Tip
Core Tip: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with lipid accumulation caused by liver injury factors except alcohol. At present, vascular endothelial growth factor B (VEGFB) has been reported to play a special role in regulating lipid metabolism and improving the onset and development of NAFLD. Therefore, the use of VEGFB as a target for treatment has become the focus of current research. This review summarizes the role and potential mechanism of VEGFB in the pathogenesis of NAFLD to provide a theoretical basis for the clinical treatment of NAFLD.